Investigational drug · Phase 3
Pegtibatinase
Also called: TVT-058, OT-58, OT-058
Not approved by FDA. In 3 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Homocystinuria.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
3
3 still active
All registered trials
3
Any phase or sponsor naming "Pegtibatinase"
First trial start
2019
Jan 22, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Pegtibatinase", any sponsor or status.
Conditions studied
As listed on its trial records.
- Homocystinuria
Largest trials
Live from ClinicalTrials.gov: studies naming "Pegtibatinase" as an intervention, largest first.
- A Long-term Extension Study to Assess the Long-term Safety and Efficacy of Pegtibatinase Treatment in Participants ≥5 to ≤65 Years of Age With Classical Homocystinuria (HCU) (ENSEMBLE) (ENSEMBLE)Pivotal-lookingEnrolling by invitation
Travere Therapeutics, Inc.Industry
NCT06431893 · 100 participants (planned) · Start Apr 30, 2024 · Primary completion Aug 2030
Drug: Pegtibatinase · For: Homocystinuria
Sites: Phoenix, Arizona; New Haven, Connecticut; Atlanta, Georgia · 52 sites in all
- Pegtibatinase as a Treatment for Participants With Classical Homocystinuria (HCU) Receiving Standard of Care TreatmentPivotal-lookingRecruiting
Travere Therapeutics, Inc.Industry
NCT06247085 · 70 participants (planned) · Start Dec 28, 2023 · Primary completion Aug 2027
Drug: Pegtibatinase · For: Homocystinuria
Sites: Phoenix, Arizona; New Haven, Connecticut; Atlanta, Georgia · 52 sites in all
Travere Therapeutics, Inc.Industry
NCT03406611 · 39 participants (planned) · Start Jan 22, 2019 · Primary completion Jul 2027
Drug: Pegtibatinase; Placebo · For: Homocystinuria
Sites: Aurora, Colorado; Miami, Florida; Chicago, Illinois · 12 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Homocystinuria: Advances in metabolic and molecular therapies targeting homocysteine pathways (Review).
Althubity AA · Mol Med Rep 2026
- Safety and efficacy of pegtibatinase enzyme replacement therapy in adults with classical homocystinuria in the COMPOSE phase 1/2 randomized trial.
Ficicioglu C, Thomas JA, Ganesh J, et al. · Genet Med 2025
- Current and Novel Therapeutical Approaches of Classical Homocystinuria in Childhood With Special Focus on Enzyme Replacement Therapy, Liver-Directed Therapy and Gene Therapy.
Bittmann S, Villalon G, Moschuring-Alieva E, et al. · J Clin Med Res 2023
- Recent therapeutic approaches to cystathionine beta-synthase-deficient homocystinuria.
Majtan T, Kožich V, Kruger WD · Br J Pharmacol 2023
- Interplay of Enzyme Therapy and Dietary Management of Murine Homocystinuria.
Park I, Bublil EM, Glavin F, et al. · Nutrients 2020
- Long-term uninterrupted enzyme replacement therapy prevents liver disease in murine model of severe homocystinuria.
Park I, Hůlková H, Krijt J, et al. · Hum Mutat 2020
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.